A decade of transcription factor-mediated reprogramming to pluripotency.
Level 5 - mechanism / opinion, no new human data
Narrative review of basic molecular biology and cellular mechanisms without human clinical data.
PubMed 26883003 · doi:10.1038/nrm.2016.8
What was done
This narrative review summarizes ten years of progress in transcription factor-mediated cell fate reprogramming to pluripotency in vitro, focusing on the four original factors (OCT3/4, SOX2, KLF4, and MYC) and recent mechanistic and efficiency advancements.
What was found
The abstract reports no numerical data or quantitative metrics. It notes qualitatively that pluripotency induction requires a defined cocktail of transcription factors, that mechanistic understanding of reprogramming has grown but remains incomplete, and that protocols have become more efficient for translational applications.
Why it matters
It provides a high-level historical and mechanistic synthesis of the development of induced pluripotent stem cell technology and its potential utility in regenerative medicine, disease modeling, and drug discovery.
Limits
The abstract contains no quantitative findings, effect sizes, or specific parameters. As a narrative review of laboratory mechanisms, it lacks systematic search methodology, structured risk-of-bias evaluation, and direct human clinical outcome data.
Cited by
- supports The Yamanaka factors, which allow reprograming a somatic cell into an induced pluripotent stem cell, were discovered in 2006.